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Background: HIV and combination antiretroviral therapy (cART) may increase cardiovascular disease (CVD) risk. We
assessed the early effects of cART on CVD risk markers in a population with presumed low CVD risk.
Methods: Adult patients (n=118) in Lusaka, Zambia were recruited at the time of initiation of cART for HIV/AIDS.
Cardiometabolic risk factors were measured before and 90 days after starting cART. Participants were grouped
according to cART regimens: Zidovudine + Lamivudine + Nevirapine (n=58); Stavudine + Lamivudine + Nevirapine
(n=43); and ‘other’ (Zidovudine + Lamivudine + Efavirenz, Stavudine + Lamivudine + Efavirenz, Tenofovir +
Emtricitabine + Efavirenz or Tenofovir + Emtricitabine + Nevirapine, n=17). ANOVA was used to test whether
changes in cardiometabolic risk markers varied by cART regimen.
Results: From baseline to 90 days after initiation of cART, the prevalence of low levels of high-density lipoprotein
cholesterol (<1.04 mmol/L for men and <1.30 mmol/L for women) significantly decreased (78.8% vs. 34.8%,
P<0.001) while elevated total cholesterol (TC ≥5.18 mmol/L, 5.1% vs. 11.9%, P=0.03) and the homeostasis model
assessment of insulin resistance ≥3.0 (1.7% vs. 17.0%, P<0.001) significantly increased. The prevalence of TC:HDL-c
ratio ≥5.0 significantly decreased (44.9% vs. 6.8%, P<0.001). These changes in cardiometabolic risk markers were
independent of the cART regimen.
Conclusion: Our results suggest that short-term cART is associated with a cardioprotective lipid profile in Zambia
and a tendency towards insulin resistance regardless of the cART regimen.
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HIV/AIDS patients have increased risk for adverse cardio-
vascular outcomes and diabetes [1-3]. Both the HIV infec-
tion and combination antiretroviral therapy (cART) are
independently associated with increased cardiometabolic
risk [4,5].
Studies, mainly from developed countries, have shown
that certain cART regimens, particularly combinations
containing protease inhibitors, are associated with in-
creased serum triglycerides (TG), low-density lipoprotein
cholesterol (LDL-c) and total cholesterol (TC) as well as
insulin resistance, while little or no effect is seen on high-* Correspondence: edmond.kabagambe@vanderbilt.edu
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reproduction in any medium, provided the ordensity lipoprotein cholesterol (HDL-c) [6-8]. This constel-
lation of dyslipidemia, especially elevation of TC:HDL-c
ratio, and insulin resistance is thought to enhance the
process of atherosclerosis, thus partly explaining the link
between cART and adverse cardiometabolic outcomes
[9-11]. Although protease inhibitor sparing combinations
have also been associated with similar lipid changes, they
result in substantial HDL-c elevation and relatively lower
elevations of TG and LDL-c [6]. This lipid profile, espe-
cially the elevation of HDL-c, is thought to be beneficial to
cardiovascular health [6,11,12].
However, few studies have explored the association be-
tween cART and cardiovascular health within resource-
constrained settings where the majority of HIV/AIDS
cases reside and where the prevalence of traditional car-
diovascular risk factors, such as excess adiposity, a high
fat diet, and smoking, may be lower [13-15]. Findingstd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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settings due to factors that could potentially modify cardio-
vascular risk e.g., age of the population, differences in HIV
subtypes, diet, lifestyle as well as genetics [14]. The ongoing
expansion of the cART programs within resource-limited
settings highlights the need to quantify cardiometabolic
risk associated with different antiretroviral combinations in
these settings [15,16].
Using serum lipids and markers of insulin resistance as
cardiometabolic risk markers, we investigated changes in
cardiometabolic risk following cART among treatment-
naïve HIV positive patients initiating therapy in Zambia.
We also tested whether the changes in cardiometabolic
risk markers varied by cART regimen.
Methods
Ethics statement
The study was approved by the Institutional Review
Board of the University of Alabama at Birmingham
(UAB) and the Research Ethics Committee of the Uni-
versity of Zambia. All participants gave written informed
consent.
Study design and population
The current analysis is based on data from the Diet,
Genetic Polymorphisms in Lipid-Metabolizing Enzyme
genes, and Antiretroviral Therapy-Related Dyslipidemia
(DGPLEAD) study which was carried out in Chawama
Clinic, Lusaka, Zambia. The study has been described
elsewhere [17]. In brief, 210 cART-naïve HIV/AIDS pa-
tients were recruited between January and December
2007. Men and women aged 16.5-60 years who were eli-
gible to begin cART according to the Zambia HIV na-
tional guidelines and had BMI ≥16 kg/m2 and CD4+
lymphocyte count ≥50 cells/μL were invited into the
study. All participants who gave consent were enrolled.
The aforementioned BMI and CD4+ criteria were used
because another study in the same clinic simultaneously
recruited participants with BMI and CD4+ levels below
these thresholds [18]. cART was prescribed according to
the Zambian national guidelines at the time. Regimens
comprised 2 nucleoside reverse transcriptase inhibitors
(NRTI), for example zidovudine [AZT] and lamivudine
[3TC] or stavudine [D4T] and lamivudine [3TC], and a
non-nucleoside reverse transcriptase inhibitor, for ex-
ample efavirenz [EFV] or nevirapine [NVP]. Tenofovir
[TDF] and emtricitabine [FTC] were introduced into the
first-line NRTI backbone in July 2007, while the study
was underway [19]. No protease inhibitors were included
in the regimens.
Data collection
At the initial visit, data on smoking, physical activity
and alcohol intake were collected using standardizedquestionnaires. In addition, dietary intake was assessed
using 24-hour dietary recalls; the Nutrition Data System
for Research software was used to determine dietary
nutrient content. Zambian foods not in the database
were substituted with similar foods in the database
using a recommended guideline [17]. Also added into
the database were recipes for common foods which
were collated through focus group meetings.
Anthropometric measurements including weight, height,
waist circumference, hip circumference and mid-upper
arm circumference were recorded as an average of two
measurements made by a trained staff member. A blood
specimen was taken from each participant after an 8-hour
fast to determine lipid and metabolic profiles. Participants
were followed, and their lipid and metabolic profiles and
vital status were reassessed at 90 days following cART
initiation.Laboratory tests
Lipids and glucose were assayed using the Roche
Cobas Integra 400+ auto analyzer (Roche Diagnostics,
Indianapolis, IN, USA). An enzymatic colorimetric assay
was used to measure TG, LDL-c and TC concentrations
while a homogeneous enzymatic colorimetric assay was
used to measure HDL-c. In addition, the hexokinase en-
zyme method was used to measure glucose concentration
while insulin was assayed using chemiluminescence on the
Roche Elecsys 2010 autoanalyzer. Serum albumin, creatin-
ine and high-sensitivity C-reactive protein (CRP) were mea-
sured on a Roche Modular P analyzer using bromocresol
purple assay for albumin and immunoturbidimetric assay
for CRP (Roche Diagnostics, Indianapolis, IN, USA).Statistical analysis
Only participants with both baseline and 90-day lipid and
other metabolic measurements were included in the
current analysis. cART regimens were grouped into 3 cat-
egories as follows: AZT+3TC+NVP, D4T+3TC+NVP and
‘other’ (AZT+3TC+EFV, D4T+3TC+EFV, TDF+FTC+EFV
or TDF+FTC+NVP). We compared baseline characteris-
tics of participants by cART regimen using one-way
ANOVA and Kruskal-Wallis tests for continuous variables
and chi-square tests for categorical variables. We then
tested lipid, insulin and glucose changes from baseline to
90 days using paired t-tests and Wilcoxon signed-rank
tests. We stratified the data by the antiretroviral combina-
tions and again tested whether changes were significant
using Wilcoxon signed-rank tests. We used ANOVA
models with robust variance estimators to determine
whether the magnitude of changes in cardiometabolic
markers varied by cART regimen; change from baseline to
90-day was the dependent variable and cART regimen and
sex were the independent variables. Sex was included in
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by cART regimen (Table 1).
We used the US National Cholesterol Education Program
Adult Treatment Panel III guidelines [10] to define abnor-
mal lipid values as follows: TG ≥1.70 mmol/L (150 mg/dL),
LDL-c ≥3.37 mmol/L (130 mg/dL), TC ≥5.18 mmol/L
(200 mg/dL), and HDL-c <1.04 mmol/L (40 mg/dL) in
men and <1.30 mmol/L (50 mg/dL) in women. We also de-
fined TC:HDL-c ratio ≥5.0 and glucose ≥5.55 mmol/L
(100 mg/dL) as abnormal [13,20]. Participants with a
homeostasis model assessment of insulin resistance
(HOMA-IR) index ≥3.0 were considered to be insulin re-
sistant [21,22]. HOMA-IR was calculated using the follow-
ing formula: fasting serum insulin (μU/mL) × fasting
plasma glucose (mmol/L)/22.5 [23]. We used McNemar’s
test to compare the prevalence of the abnormal values be-
tween baseline and 90 days. We repeated the analysis for
HDL-c after redefining low HDL-c as <1.04 mmol/L
(<40 mg/dL) for both men and women to enable compari-
son with previous studies.
To determine the potential for selection bias, we com-
pared baseline characteristics of participants who were
included to those who were excluded from the current
analysis. All analyses were done using SAS version 9.2
(SAS Institute Inc., Cary, NC, USA); differences were
considered significant at P≤0.05.Results
Of the 210 participants recruited into the DGPLEAD
study, 134 had both baseline and 90-day information.
We excluded 16 more participants for missing data on
TC, HDL-c, LDL-c and medications, leaving 118 partici-
pants for the current analysis. Their summary statistics
are shown in Table 1.Baseline characteristics
The mean age±SD of the study population was 35.0±
7.9 years; 55.5% were women. The majority of the partici-
pants (85.6%) were either on AZT+3TC+NVP or D4T
+3TC+NVP. Participants in various antiretroviral combin-
ation groups were similar (P>0.05) with regard to age, body
mass index (BMI; weight (kg)/height[m]2), waist circumfer-
ence, hip circumference, mid-upper arm circumference,
smoking, alcohol drinking, nutrient intake and lipid profiles
at baseline. The majority of participants on AZT+3TC
+NVP were men while women were the majority in the
D4T+3TC+NVP and ‘other’ cART regimens. Participants
on D4T+3TC+NVP, had a lower mean weight (P=0.01) and
height (P<0.001), had a higher median CRP (P=0.01) and a
higher proportion of high CRP (≥3.0 mg/dL; P=0.05) com-
pared to the participants on AZT+3TC+NVP or ‘other’
cART regimens. In addition, participants on D4T+3TC
+NVP had a lower mean serum albumin (P<0.001) and ahigher proportion of low serum albumin (<3.5 g/dL;
P<0.001).Changes from baseline to 90 days
Table 2 shows lipid and other metabolic changes from
baseline to 90 days. Total cholesterol, LDL-c and HDL-c
concentrations significantly increased (P<0.001, P=0.02
and P<0.001, respectively); the increase in HDL-c was pro-
portionately greater than that of TC, yielding a significant
decrease in the TC:HDL-c ratio (P<0.001). Insulin and
HOMA-IR doubled (P<0.001 in both cases), while glucose
and BMI increased significantly but less substantially
(P=0.05 and P<0.001, respectively). There was no signifi-
cant change in TG concentrations (P=0.36).
Analyses stratified by cART regimen (Table 3)
showed significant increases (P<0.05) in HDL-c and
decreases in TC:HDL-c ratio from baseline to 90 days
in all cART regimens. In addition, there were in-
creases in TC, insulin, HOMA-IR and BMI across all
3 cART regimens, though this increase was statisti-
cally significant (P<0.05) only in the AZT+3TC+NVP
and D4T+3TC+NVP cART groups and not in the
‘other’ group (P>0.05). Furthermore, only the group
on D4T+3TC+NVP had a significant increase in LDL-c
(P=0.02), while none of the groups exhibited a significant
change (P>0.05) in TG.
Except for TC (P=0.04), none of the changes in
cardiometabolic risk markers varied significantly by treat-
ment group in analyses adjusted for sex (Table 3). In
models further adjusted for age and BMI, the P-values for
the treatment regimen remained essentially unchanged.Prevalence of lipid and metabolic abnormalities at
baseline and 90 days
As shown in Figure 1, the prevalence of TC ≥5.18 mmol/L
significantly increased (5.1% vs. 11.9%, P=0.02) while the
prevalence of low HDL-c (<1.04 mmol/L (<40 mg/dL) in
men and <1.30 mmol/L (<50 mg/dL) in women), TC:
HDL-c ≥5.0 and BMI <18.5 kg/m2 significantly decreased
(P<0.05) from baseline to 90 days. In addition, the
prevalence of HOMA-IR ≥3.0 significantly increased from
baseline to 90 days (P<0.001).
Analysis of HDL-c after redefining low HDL-c as
<1.04 mmol/L for both men and women still showed a
significant decrease from baseline to 90 days (baseline:
72.9% vs. 90-day: 21.2%, P<0.001, respectively). Al-
though there were nominal elevations in the prevalence
of LDL-c ≥3.37 mmol/L (≥130 mg/dL) and glucose
>5.55 mmol/L (>100 mg/dL), the changes were not sta-
tistically significant (P=0.48 and P=0.17, respectively).
There was no change in the prevalence of triglycerides
≥1.70 mmol/L (≥150 mg/dL, P=0.83).
Table 1 Baseline characteristics of the DGPLEAD study overall and by combination antiretroviral therapy
Combination antiretroviral therapy
Variable Overall (n = 118) AZT+3TC+NVP (n = 58) D4T+3TC+NVP (n = 43) Other ‡ (n = 17) P *
Age, years† 35.0 ± 7.9 36.7 ± 7.5 33.3 ± 7.3 33.5 ± 9.7 0.07
Gender, % female 55.9 41.4 72.1 64.7 0.01
BMI, kg/m2 20.2 ± 2.7 20.2 ± 2.7 20.0 ± 2.4 20.3 ± 3.5 0.86
BMI, %
< 18.5 kg/m2 29.7 27.6 27.9 41.2 0.63
18.5 - 24.9 kg/m2 63.6 67.2 65.1 47.1
≥ 25.0 kg/m2 6.8 5.2 7.0 11.8
Weight, kg 54.9 ± 8.7 57.2 ± 9.0 51.9 ± 7.1 54.4 ± 9.7 0.01
Height, m 1.65 ± 0.08 1.68 ± 0.07 1.61 ± 0.07 1.64 ± 0.07 < 0.001
Waist circumference, cm 72.9 ± 6.7 73.8 ±7.2 72.7 ± 6.0 70.2 ± 6.3 0.16
Hip circumference, cm 89.1 ± 7.0 90.1 ± 7.4 88.1 ± 6.2 88.2 ± 7.7 0.32
MUAC, cm 24.9 ± 2.6 25.4 ± 2.7 24.2 ± 2.1 24.9 ± 2.9 0.06
Current smoker, % † 4.4 7.1 2.3 0.0 0.33
Current drinker, % † 9.6 14.3 4.7 6.3 0.24
Total energy intake, kcal/day 1750 ± 651 1840 ± 641 1620 ± 604 1770 ± 773 0.25
Total fat, % energy/day 31.7 ± 10.8 29.3 ± 9.5 34.0 ± 11.2 34.5 ± 12.4 0.05
MUFA, % energy/day 9.1 ± 3.5 8.3 ± 3.0 9.8 ± 4.2 9.8 ± 3.1 0.07
PUFA, % energy/day 14.1 ± 5.9 12.8 ± 5.0 15.2 ± 5.9 15.4 ± 7.9 0.07
Saturated fat, % energy/day 6.3 ± 2.5 6.0 ± 2.5 6.6 ± 2.7 6.8 ± 2.4 0.37
Carbohydrates, % energy/day 56.1 ± 12.4 58.0 ± 11.5 54.2 ± 12.8 54.5 ± 14.3 0.27
Proteins, % energy/day 12.9 ± 3.9 13.4 ± 4.2 12.6 ± 4.0 12.0 ± 2.2 0.34
CD4 count, cells/μL 136 ± 50 137 ± 45 133 ± 51 138 ± 65 0.87
CRP, mg/L † 9.48 [2.04, 25.94] 5.62 [1.31, 17.36] 16.62 [5.51, 44.31] 4.05 [1.64, 25.62] 0.01
CRP ≥ 3.0 mg/L, % † 70.4 63.5 84.6 58.8 0.05
Albumin, g/dL † 3.11 ± 0.71 3.44 ± 0.59 2.67 ± 0.64 3.14 ± 0.67 < 0.001
Albumin < 3.5 g/dL, % † 65.7 48.1 89.7 64.7 < 0.001
Creatinine ≥ 2.0 mg/dL, % † 0.93 0.0 2.6 0.0 0.41
Fasting insulin, μU/mL † 3.00 [1.90, 5.40] 3.00 [2.00, 5.00] 3.00 [1.50, 5.00] 2.60 [1.20, 5.90] 0.80
Fasting glucose, mmol/L † 3.80 [3.40, 4.10] 3.90 [3.60, 4.30] 3.70 [3.40, 4.10] 3.60 [3.00, 3.90] 0.02
HOMA-IR 0.51 [0.30, 0.98] 0.53 [0.33, 0.93] 0.50 [0.28, 1.00] 0.45 [0.16, 0.98] 0.63
Total cholesterol, mmol/L 3.56 ± 0.83 3.68 ± 0.75 3.42 ± 0.92 3.52 ± 0.86 0.27
Triglycerides, mmol/L 1.02 [0.85, 1.37] 1.01 [0.86, 1.33] 1.16 [0.88, 1.60] 0.95 [0.77, 1.05] 0.15
LDL-cholesterol, mmol/L 2.12 ± 0.75 2.26 ± 0.62 1.93 ± 0.89 2.10 ± 0.68 0.10
HDL-cholesterol, mmol/L 0.72 [0.52, 1.09] 0.80 [0.61, 1.15] 0.65 [0.34, 0.92] 0.76 [0.57, 1.03] 0.08
TC:HDL-c ratio 4.77 [3.51, 6.30] 4.54 [3.44, 5.84] 5.32 [3.97, 8.93] 4.34 [3.33, 5.82] 0.15
DGPLEAD, Diet, Genetic Polymorphisms in Lipid-Metabolizing Enzyme genes, and Antiretroviral Therapy-Related Dyslipidemia; BMI, Body Mass Index; MUAC, Mid
Upper Arm Circumference; MUFA, Monounsaturated Fatty Acids; PUFA, Polyunsaturated Fatty Acids; CRP, C-reactive Protein; LDL, Low Density Lipoprotein; HDL,
High Density Lipoprotein; TC, Total Cholesterol; HOMA-IR, Homeostatic model assessment of insulin resistance.
Values are reported as mean ± standard deviation, median [25th percentile, 75th percentile] or percent.
‡ AZT + 3TC + EFV, D4T + 3TC + EFV, TDF + FTC + EFV, or TDF+FTC+NVP.
* P-values for the comparison between cART regimens were obtained through one-way ANOVA or Kruskal-Wallis tests for continuous variables and from
Chi-square tests for categorical variables.
† Variables with missing values – 1 for glucose, 2 for age, 3 for both smoking and alcohol status, 10 for CRP, albumin and creatinine and 20 for insulin.
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Table 2 Lipid and metabolic changes from baseline to 90 days of combination antiretroviral therapy
Variable Baseline (n = 118) End (n = 118) P* for change
HDL-cholesterol, mmol/L 0.72 [0.52, 1.09] 1.34 [1.09, 1.70] < 0.001
LDL-cholesterol, mmol/L 2.12 ± 0.75 2.28 ± 0.59 0.02
Total cholesterol, mmol/L 3.56 ± 0.83 4.09 ± 0.86 < 0.001
Triglycerides, mmol/L 1.02 [0.85, 1.37] 1.03 [0.79, 1.37] 0.36
TC:HDL-c ratio 4.77 [3.51, 6.30] 2.93 [2.38, 3.69] < 0.001
Insulin, μU/mL 3.00 [1.90, 5.40] 6.40 [3.40, 12.50] < 0.001
Glucose, mmol/L 3.80 [3.40, 4.10] 4.00 [3.40, 4.50] 0.048
HOMA-IR 0.51 [0.30, 0.98] 1.12 [0.61, 2.21] < 0.001
BMI, kg/m2 20.15 ± 2.70 20.89 ± 2.92 < 0.001
Weight, kg 54.9 ± 8.7 56.8 ± 9.0 < 0.001
Values are reported as mean ± standard deviation or median [25th percentile, 75th percentile].
* P-values obtained from paired t-tests or Wilcoxon Signed rank tests.
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A comparison between participants whose data were in-
cluded vs. excluded from the current analysis showed that
the two groups were similar (P>0.05) with regard to sex,
BMI, waist circumference, hip circumference, mid-upper
arm circumference, smoking, CD4 cell count, CRP, serum
albumin, TG, HDL-c, TC:HDL-c ratio, and intakes of alco-
hol, total energy and % energy from total fat, monounsatu-
rated fat, polyunsaturated fat, saturated fat, proteins and
carbohydrates. However, excluded participants had a sig-
nificantly lower mean age compared to those included in
the study (32.7±6.4 SD years vs. 35.0±7.9 years in those in-
cluded, P=0.03). In addition, excluded participants had
lower mean LDL-c (1.82±0.77 SD mmol/L vs. 2.12±0.75
mmol/L in those included, P=0.01) and TC (3.30±1.03
mmol/L vs. 3.56±0.83 mmol/L in those included, P=0.04).
Discussion
This study showed that in the first 90 days, cART regi-
mens prescribed to HIV/AIDS patients in Zambia in
2007 were associated with moderate increases in LDL-c
and TC and substantial increases in HDL-c, leading to a
substantial reduction in the TC:HDL-c ratio. Serum in-
sulin, glucose and the HOMA-IR index also increased,
suggesting a tendency towards insulin resistance. These
changes were independent of the cART regimen.
The observed short-term lipid and metabolic changes
are not likely to be associated with an increase in the risk
of adverse cardiovascular outcomes since they mostly
remained below established cut-points for increased car-
diovascular disease risk in developed countries. The actual
lipid cut-points associated with cardiovascular risk in de-
veloping countries are unknown. The significant increase
in HDL-c and the consequent decrease in the TC:HDL-c
ratio may suggest a cardioprotective effect of antiretroviral
therapy [7,10,24,25]. This finding is consistent with resultsfrom the 2NN trial in which NVP compared to EFV con-
ferred a better lipid profile [26]. The overall improved lipid
profile in our study could in part be due to the fact that
95% of the patients were on NVP-based therapy. The ob-
served improved lipid profile is of great interest given pre-
vious reports have suggested increased cardiovascular risk
by HIV itself as well as by some cART [1,3]. The margin-
ally significant difference in TC change among the three
cART regimens was driven by the change in the ‘other’
group which, although smaller, was similar in direction to
the change in the two main cART regimens. In addition to
comprising many cART regimens (including AZT and
D4T), the ‘other’ group has a small sample size (n=17),
making the observed value more likely due to chance.
In agreement with our study findings, a two-year pro-
spective study conducted in Uganda by Buchacz et al.
[13] among 374 cART-naïve patients showed that TC
and HDL-c were significantly higher (P<0.05) at one and
two years following initiation of therapy compared to
the baseline values. Buchacz et al. also showed that the
TC:HDL-c ratio was significantly lower at one and two
years compared to the baseline value. Additionally, a
cross-sectional study among HIV/AIDS patients initiat-
ing cART in Tanzania reported lipid values that are
comparable to those observed in the current study [14].
Furthermore, concordant with our findings, cross-
sectional studies in Kenya [27] and India [28] comparing
cART-naïve and treated groups showed that patients on
cART had significantly higher (P<0.05) TC, LDL-c and
HDL-c.
Moreover, in agreement with our findings, a study
conducted in Cameroon by Yone et al. [29] compared
cART-naïve HIV/AIDS patients with patients who had
been on first-line cART for 12 months and reported that
patients on cART had higher TC and LDL-c. Contrary
to our findings, Yone et al. reported that patients on
Table 3 Comparison of metabolic changes by period and combination antiretroviral therapy regimen in the DGPLEAD study
AZT+3TC+NVP (n = 58) D4T+3TC+NVP (n = 43) Other (n = 17) Global
P**Variable Baseline End P* Baseline End P* Baseline End P*
HDL-c, mmol/L 0.80 [0.61, 1.15] 1.42 [1.17, 1.73] < 0.001 0.65 [0.34, 0.92] 1.27 [1.02, 1.70] < 0.001 0.76 [0.57, 1.03] 1.22 [0.96, 1.47] 0.003 0.22
LDL-c, mmol/L 2.24 [1.76, 2.52] 2.25 [2.00, 2.75] 0.51 2.01 [1.44, 2.42] 2.27 [1.81, 2.61] 0.007 2.06 [1.71, 2.58] 2.14 [1.84, 2.18] 0.41 0.13
TC, mmol/L 3.59 [3.23, 3.99] 4.00 [3.50, 4.68] < 0.001 3.46 [2.85, 4.08] 4.13 [3.59, 4.58] < 0.001 3.40 [2.86, 3.87] 3.50 [3.40, 3.73] 0.77 0.04
TC:HDL-c ratio 4.54 [3.44, 5.84] 2.78 [2.34, 3.49] < 0.001 5.32 [3.97, 8.93] 3.08 [2.85, 3.94] < 0.001 4.34 [3.33, 5.82] 2.73 [2.31, 3.00] 0.001 0.36
TG, mmol/L 1.01 [0.86, 1.33] 1.06 [0.70, 1.41] 0.93 1.16 [1.88, 1.60] 1.05 [0.85, 1.44] 0.41 0.95 [0.77, 1.05] 0.91 [0.68, 1.14] 0.17 0.33
Insulin, μU/mL 3.00 [2.00, 5.00] 6.70 [4.00, 12.50] < 0.001 3.00 [1.50, 5.00] 7.65 [3.00, 13.45] < 0.001 2.60 [1.20, 5.90] 4.65 [3.15, 9.70] 0.07 0.18
Glucose, mmol/L 3.90 [3.60, 4.30] 4.20 [3.60, 4.60] 0.37 3.70 [3.40, 4.10] 3.80 [3.20, 4.60] 0.23 3.60 [3.00, 3.90] 3.70 [3.50, 4.20] 0.17 0.79
HOMA-IR 0.53 [0.33, 0.93] 1.12 [0.62, 2.41] < 0.001 0.50 [0.28, 1.00] 1.39 [0.49, 2.49] < 0.001 0.45 [0.16, 0.98] 0.72 [0.49, 1.53] 0.08 0.07
BMI, kg/m2 20.1 [18.2, 21.5] 20.3 [19.1, 22.2] 0.001 19.6 [18.4, 21.1] 20.6 [19.2, 22.4] < 0.001 19.4 [17.6, 22.4] 20.1 [18.6, 22.3] 0.49 0.26
Weight, kg 55.3 [51.0, 62.0] 58.0 [53.5, 64.0] 0.001 52.0 [46.0, 55.0] 56.0 [47.0, 59.0] < 0.001 53.0 [49.0, 60.5] 55.0 [50.0, 57.0] 0.49 0.30
Values are reported as median [25th percentile, 75th percentile].
* P-values obtained through Wilcoxon signed rank tests.
** P-values are from ANOVA with robust variance estimators comparing changes from baseline to 90 days after initiating cART and are adjusted for sex.





















Figure 1 Prevalence of abnormal lipid and other
cardiometabolic risk factors at baseline and 90 days following
cART initiation in the DGPLEAD study. Comparing baseline
measurements to those at 90 days following initiation of therapy,
there was a significant change in the proportion of patients with
low HDL-c (P<0.001), TC ≥5.18 mmol/L (P=0.03), TC:HDL-c ≥ 5.0
(P<0.001), HOMA-IR ≥3.0 (P<0.001) and BMI <18.5 (P<0.001). There
was no significant change (P>0.05) in LDL-c ≥3.37 mmol/L,
triglycerides ≥1.70 mmol/L and glucose ≥5.55 mmol/L. * Low HDL-c
was defined as <1.04 mmol/L in men and <1.30 mmol/L in women.
BMI, Body Mass Index; HDL-c, High Density Lipoprotein Cholesterol;
HOMA-IR, Homeostasis Model Assessment of Insulin Resistance; LDL-
c, Low Density Lipoprotein Cholesterol; TC, Total Cholesterol.
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naïve patients and also a higher TC:HDL-c ratio. Due to
the cross-sectional study design, it is impossible to know
whether the HDL-c concentration and the TC:HDL-c ra-
tio among patients on cART improved or worsened fol-
lowing initiation of therapy. In addition, this study [29]
only included patients who did not switch medications,
which may have introduced selection bias.
Our study findings also indicate a significant increase
(P<0.05) in serum insulin concentration, glucose and
HOMA-IR index in the AZT+3TC+NVP and D4T
+3TC+NVP cART regimen groups, suggesting that
cART may increase insulin resistance [22,30]. Similar
observations have been reported by Pujari et al. in
India [28]. Moreover, studies from developed countries
using the euglycemic clamp protocol to assess insulin
resistance have shown that NRTIs, particularly AZT or
D4T, are associated with increased insulin resistance
[31,32]. Our results should be corroborated using more
accurate measures of insulin resistance; if confirmed, it
may be a concern because insulin resistance is an
established risk factor for diabetes mellitus and cardio-
vascular disease [33,34].
About 44% of the recruited patients were excluded,
mainly due to early termination of the study [17],raising a concern for selection bias. A comparison be-
tween patients whose data were included to those
whose data were excluded indicates that the excluded
patients were younger, had lower LDL-c and lower TC
but similar in most other characteristics at baseline. Al-
though age is a known modulator of cardiovascular risk
[10], little is known about the effect of age on the risk
for adverse cardiovascular outcomes in young people,
and we speculate that a 2.3 years age difference between
those included and those excluded in a young popula-
tion may not result in a clinically meaningful risk differ-
ence. In addition, despite the slight differences in LDL-c
and TC, the two groups had similar HDL-c and TC:
HDL-c ratios, suggesting that they did not differ with
regard to risk for adverse cardiovascular outcomes [10].
It is also noteworthy that despite the lipid differences,
the mean TC level for the included and excluded pa-
tients was still much lower than the 200 mg/dL cut-
point. Moreover, the two groups were similar in com-
position by sex, anthropometric measures, nutritional
status, and serum inflammatory marker levels, all of
which are strong modulators of cardiometabolic risk
[10,35-40].
Unlike studies conducted in developed countries, none
of the participants in our study reported use of any
lipid-lowering drugs, eliminating confounding from such
medications.
We acknowledge a number of limitations in our
study. First, the study lacked a control group which
makes it difficult to differentiate the effect of regression
to the mean from the effect of cART. Second, we were
not able to measure CRP concentrations at the 90-day
follow-up. CRP is a strong correlate of cardiometabolic
risk [3]. Third, we lacked baseline viral load values be-
cause they were not part of standard of care in Zambia
at the time of the study and could not be measured for
the current analysis due to financial constraints. Viral
load measurements are important markers of disease
progression in HIV infected patients and could influ-
ence response to antiretroviral therapy. However, the 3
cART regimen categories had similar CD4 cell counts
(P=0.87) indicating no obvious differences in disease
progression between the 3 treatment categories. Fourth,
our study had a short follow-up period of 90 days, a
period during which underweight or emaciated pa-
tients may still be resetting their metabolic profiles fol-
lowing treatment. However, the few studies in resource
poor settings that have followed patients for a longer
period (up to 24 months) have reported similar associ-
ations [13].
Nevertheless, larger and longer studies are warranted
to examine the effects of different cART regimens on
cardiometabolic risk and outcomes in sub-Saharan
African populations.
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Our results suggest that first-line cART regimens in
Zambia that did not include protease inhibitors are as-
sociated with cardioprotective lipid profiles character-
ized by a substantial increase in HDL-c and a decrease
in the TC:HDL-c ratio. Our findings of increased insulin
and HOMA-IR suggest a tendency towards insulin re-
sistance. These results appear to be independent of the
cART regimen used.
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